Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linvoseltamab in relapsed or refractory systemic light chain amyloidosis
2023-507809-34-00Phase 2Authorised
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 11
01
Overview
Phase 2, randomised, open-label trial of linvoseltamab in light-chain amyloidosis (3 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Incidence of dose-limiting toxicities and Hematologic complete response. Planned start Aug 2024; status: authorised.
02
Drugs
linvoseltamab
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on 2023-507809-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507809-34-00.